Dermatology
| Alopecia Areata
Dermatology
Alopecia Areata
Deuruxolitinib (CTP-543) achieves significant regrowth of scalp hair in adult patients with moderate to severe alopecia areata: Efficacy results from the multinational, double-blind, placebo-controlled THRIVE-AA2 Phase 3 trial
book_2
Source:
EADV Congress 2023 - Poster session
calendar_today
Published on Medfyle:
November 2023
In this medfyle
This poster presented at EADV 2023 shares key efficacy outcomes from the randomized, placebo-controlled THRIVE-AA2 trial in patients with moderate-to-severe AA. Results show clinically meaningful improvements in scalp hair regrowth.
Presenting Author
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the EADV Congress 2023. The content is developed by Infomedica in collaboration with the EADV.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, or the EADV.
©2023 Infomedica. All rights reserved.
